The Geriatric Nutritional Risk Index Predicts Prognosis in Japanese Patients with LATITUDE High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Multi-Center Study

The Geriatric Nutritional Risk Index Predicts Prognosis in Japanese Patients with LATITUDE High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Multi-Center Study

Malnutrition is associated with prognosis in cancer. The geriatric nutritional risk index (GNRI), based on the ratio of actual to ideal body weight and also serum albumin level, is a simple screening tool for assessing nutrition. We investigated the GNRI as a prognostic factor for oncological outcom...

Full description

Bibliographic Details
Main Authors:	Taku Naiki, Kiyoshi Takahara, Hiromitsu Watanabe, Keita Nakane, Yosuke Sugiyama, Takuya Koie, Ryoichi Shiroki, Hideaki Miyake, Takahiro Yasui
Format:	Article
Language:	English
Published:	MDPI AG 2023-11-01
Series:	Cancers
Subjects:	abiraterone acetate aged androgen antagonists bicalutamide nutrition assessment
Online Access:	https://www.mdpi.com/2072-6694/15/22/5333

Similar Items

Trends in the Use of Second-Generation Androgen Receptor Axis Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer and Clinical Factors Predicting Biological Recurrence
by: Keita Nakane, et al.
Published: (2023-05-01)

Making the Case for Autophagy Inhibition as a Therapeutic Strategy in Combination with Androgen-Targeted Therapies in Prostate Cancer
by: Ahmed M. Elshazly, et al.
Published: (2023-10-01)

Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade
by: Takashi Nagai, et al.
Published: (2018-03-01)

Intracranial Assessment of Androgen Receptor Antagonists in Mice Bearing Human Glioblastoma Implants
by: Nomi Zalcman, et al.
Published: (2023-12-01)

Phosphodiesterase Type-5 Inhibitor Tadalafil Modulates Steroid Hormones Signaling in a Prostate Cancer Cell Line
by: Viviana M. Bimonte, et al.
Published: (2021-01-01)

Computational Analysis of Interactions between Androgen Receptor and Bicalutamide
by: Noushin Hadian, et al.
Published: (2017-03-01)

AR mRNA stability is increased with AR-antagonist resistance via 3′UTR variants
by: D A Dart, et al.
Published: (2019-12-01)

Clinicopathological Features and Treatment Challenges in Triple Negative Breast Cancer Patients: A Retrospective Cohort Study
by: Amira ELWAN, et al.
Published: (2021-05-01)

Sequential Androgen Receptor Pathway Inhibitor in Prostate Cancer: Piling-Up The Benefits or a Case for Cross-Resistance?
by: Bertrand Tombal
Published: (2014-11-01)

Comparison of two adjuvant hormone therapy regimens in patients with high-risk localized prostate cancer after radical prostatectomy: primary results of study CU1005
by: Kun Chang, et al.
Published: (2016-01-01)

SWATH-MS Based Proteomic Profiling of Prostate Cancer Cells Reveals Adaptive Molecular Mechanisms in Response to Anti-Androgen Therapy
by: Chamikara Liyanage, et al.
Published: (2021-02-01)

Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog–Thalidomide PROTACs
by: Ga Yeong Kim, et al.
Published: (2021-04-01)

Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer
by: Sahar B. Kandil, et al.
Published: (2020-12-01)

Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer
by: Takuya Tsujino, et al.
Published: (2023-10-01)

Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer
by: Avinash Khadela, et al.
Published: (2022-12-01)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
by: Hiroji Uemura, et al.
Published: (2022-01-01)

Identification of bicalutamide resistance-related genes and prognosis prediction in patients with prostate cancer
by: Yuezheng Li, et al.
Published: (2023-04-01)

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
by: Chi-Shin Tseng, et al.
Published: (2023-06-01)

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
by: Karen A. Autio, et al.
Published: (2021-12-01)

Ailanthone: a new potential drug for castration-resistant prostate cancer
by: Shihong Peng, et al.
Published: (2017-03-01)

Structural Changes Due to Antagonist Binding in Ligand Binding Pocket of Androgen Receptor Elucidated Through Molecular Dynamics Simulations
by: Sugunadevi Sakkiah, et al.
Published: (2018-05-01)

Androgen‐targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer
by: Gregory L. Branigan, et al.
Published: (2022-07-01)

Androgen-receptor positive lacrimal sac adenocarcinoma demonstrating long-lasting response to LHRH analogue plus abiraterone treatment
by: Elena eVagia, et al.
Published: (2015-02-01)

Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer
by: Taizo Uchimoto, et al.
Published: (2021-01-01)

Therapeutic benefits of maximum androgen blockade and tolerability of bicalutamide in patients with advanced prostate cancer
by: A E Aghaji, et al.
Published: (2004-01-01)

Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy
by: Vincenza Conteduca, et al.
Published: (2020-06-01)

Acetyl-CoA Counteracts the Inhibitory Effect of Antiandrogens on Androgen Receptor Signaling in Prostate Cancer Cells
by: Peter Makhov, et al.
Published: (2022-11-01)

A Novel, Circulating Tumor Cell Enrichment Method Reduces ARv7 False Positivity in Patients with Castration-Resistant Prostate Cancer
by: Takehiko Nakasato, et al.
Published: (2020-03-01)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
by: Timothy C. Wright, et al.
Published: (2021-07-01)

DEVELOPMENT AND CLINICAL EFFECTIVENESS OF ANTIANDROGENS IN THE TREATMENT OF ADVANCED PROSTATE CANCER
by: S. V. MISHUGIN, et al.
Published: (2016-12-01)

Impact of bicalutamide, an anti-androgen on rat testis
by: Azheen Subhi Abdulrahman, et al.
Published: (2019-04-01)

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter “real life” study
by: Luca Cindolo, et al.
Published: (2017-11-01)

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial
by: Kouji Izumi, et al.
Published: (2022-07-01)

A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer
by: Jingsong Zhang, et al.
Published: (2022-10-01)

Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation
by: Michele Iuliani, et al.
Published: (2022-09-01)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
by: Xiangyun You, et al.
Published: (2023-04-01)

Assessment of androgen receptor signaling inhibitors therapy in metastatic hormone-sensitive prostate cancer
by: Jukapun Yoodee, et al.
Published: (2022-11-01)

Syncope due to non-sustained episodes of Torsade de Pointes associated to androgen-deprivation therapy use: a case presentation
by: Ximena Morales, et al.
Published: (2021-03-01)

The Use of High-Intensity Focused Ultrasound (HIFU) Plus 150mg Bicalutamide as First Line Salvage Therapy for Local Recurrent Prostate Cancer
by: Jian-zhou Cao, et al.
Published: (2021-11-01)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
by: Jian-Ri Li, et al.
Published: (2017-11-01)